Figure 4

Effect of subcutaneous administration of CSL525 at 60 mg/kg once daily in a calcinosis cutis rat model. Calcinosis cutis was induced in 24 rats by sensitization with subcutaneous vitamin D (50,000 IU/kg on days 1, 2 and 3), followed by subcutaneous injections of FeCl₃ (0.15 mg) at each of the two ventral sites in the thorax on day 4. CSL525 at 60 mg/kg (N = 12) or 0.9% NaCl (N = 12) was administered subcutaneously on a daily basis. A group of 6 healthy rats received subcutaneous 0.9% NaCl on days 1, 2, and 3, and 0.5 mL of 0.9% NaCl at each of the two ventral thoracic sites on day 4. (A) Representative images of the skin tissue surrounding the FeCl₃ injection site. Arrows indicate ectopic calcification. Scale bar: 1 cm. (B) Calcium (Ca) content in the skin tissue surrounding the FeCl₃ injection site. (C) Calcium content in femoral arteries. (D) Inhibition of calcification in the skin and femoral arteries by CSL525. Results are presented as mean ± SD. Statistical analysis: one-way ANOVA with Tukey’s post hoc test. (**) p < 0.01, (***) p < 0.001.